Mustang Bio Inc. (MBIO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy
Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.
Why are Mustang Bio shares (MBIO) up almost 500%?
The Mustang Bio stock price closed on a high yesterday, trading at $0.75. The pharmaceutical company has gone vertical in the past 24 hours, climbing 476.9% to go from $0.13 to $0.75 in a single day.
Mustang Bio Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JP Joseph Pantginis HC Wainwright & Co. | -172.31 | $3,222.14 | $124.06 | $3,098.08 | 96.15% |
Mustang Bio Inc. (MBIO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Mustang Bio Inc. ever had a stock split?
Mustang Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | Manuel Litchman CEO | NASDAQ (CM) Exchange | 62818Q302 CUSIP |
| US Country | 6 Employees | - Last Dividend | 4 Apr 2023 Last Split | 22 Aug 2017 IPO Date |
Overview
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that dedicates itself to the development of cell and gene therapies aimed at treating a broad spectrum of diseases, including hematologic cancers, solid tumors, and rare genetic diseases. Established in 2015 and based in Worcester, Massachusetts, Mustang Bio is at the forefront of medical innovation, working to translate groundbreaking scientific discoveries into therapies that could offer potential cures for patients suffering from critical illnesses. Through strategic partnerships with prestigious institutions like Nationwide Children's Hospital, CSL Behring, Mayo Clinic, Leiden University Medical Centre, and SIRION Biotech GmbH, the company is pushing the boundaries of medical science to transform cutting-edge research into lifesaving treatments.
Products and Services
MB-117 and MB-217: Gene Therapy Program for X-linked Severe Combined Immunodeficiency (X-SCID)
This revolutionary gene therapy program focuses on treating X-linked severe combined immunodeficiency, a rare and life-threatening genetic disorder of the immune system. Patients with X-SCID typically do not survive infancy without effective treatment. Mustang Bio’s MB-117 and MB-217 aim to correct the genetic defect causing the immune system deficiency, offering hope for a cure to affected individuals.
MB-106 CAR T Cell Program for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
The MB-106 program is a chimeric antigen receptor (CAR) T cell therapy designed to target and eliminate cancer cells in patients with B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. By engineering patients' T cells to better recognize and attack cancer cells, this therapy represents a promising advance in cancer treatment.
MB-101 CAR T Cell Program for Glioblastoma
Mustang Bio’s MB-101 program offers a cutting-edge CAR T cell therapy specifically developed for the treatment of glioblastoma, one of the most aggressive and deadly forms of brain cancer. By harnessing the body's own immune system to target tumor cells, MB-101 provides a novel therapeutic approach in the fight against this challenging disease.
MB-108: Next-Generation Oncolytic Herpes Simplex Virus
MB-108 represents a novel therapeutic approach in the form of an oncolytic herpes simplex virus engineered to selectively infect and destroy cancer cells. This innovative therapy is being developed to offer a new treatment option for patients with solid tumors, showcasing Mustang Bio’s commitment to expanding the horizons of cancer therapy.
